+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay



Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay



Therapeutic Drug Monitoring 30(6): 744-747



Spironolactone and potassium canrenoate (aldosterone antagonist diuretics) are often used with digoxin in clinical practice. It has been well documented in the literature that spironolactone, potassium canrenoate, and their common metabolite canrenone cross-react with several digoxin immunoassays at concentrations expected after therapeutic usage of these drugs and falsely elevate or lower serum digoxin concentrations. Recently, Abbott Laboratories marketed a new Digoxin III immunoassay for application on the AxSYM analyzer. We studied the potential interference of these compounds with this new digoxin assay. The Tina-quant assay was used as the reference method because spironolactone, potassium canrenoate, and canrenone do not interfere with serum digoxin measurement using this assay. Aliquots of drug-free serum were supplemented with therapeutic and above therapeutic concentrations of spironolactone, canrenone, and potassium canrenoate, and apparent digoxin concentrations were measured using the Digoxin III assay and Tina-quant assay. Significant apparent digoxin concentrations were observed when the Digoxin III digoxin assay was used, but no apparent digoxin levels was observed using the Tina-quant assay. When serum pools prepared from patients receiving digoxin were further supplemented with these compounds in concentrations expected in sera of patients receiving these medications, falsely elevated digoxin levels were observed using Digoxin III assay, but no statistically significant change was observed using the Tina-quant assay. We conclude that spironolactone, potassium canrenoate, and their common metabolite canrenone interfere with the serum digoxin measurements using the new Digoxin III assay.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052829467

Download citation: RISBibTeXText

PMID: 18824952

DOI: 10.1097/ftd.0b013e31818b0e6a


Related references

Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin. Journal of Clinical Laboratory Analysis 16(4): 172-177, 2002

Interference of spironolactone, potassium canrenoate and canrenone in digoxin immunoassay can be eliminated by a new turbidimetric digoxin assay on the Bayer ADVIA 1650 system. Clinical Chemistry 49(S6): A82, 2003

A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone. Therapeutic Drug Monitoring 25(4): 478-482, 2003

Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay. Journal of Clinical Laboratory Analysis 26(3): 143-147, 2012

Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone. Therapeutic Drug Monitoring 33(1): 128-131, 2011

Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay. Journal of Clinical Laboratory Analysis 24(6): 413-417, 2011

A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone. Journal of Clinical Laboratory Analysis 20(5): 204-208, 2006

Effect of Chinese medicines Chan Su and Lu-Shen-Wan on serum digoxin measurement by Digoxin III, a new digoxin immunoassay. Therapeutic Drug Monitoring 30(1): 95-99, 2008

Effect of endogenous digoxin-like immunoreactive factors on serum digoxin measurement by a new turbidimetric digoxin immunoassay. Clinical Chemistry 49(S6): A78, 2003

Interference of endogenous digoxin-like immunoreactive factors in serum digoxin measurement is minimized in a new turbidimetric digoxin immunoassay on ADVIA 1650 analyzer. Therapeutic Drug Monitoring 26(1): 85-89, 2004

Effect of Asian ginseng, Siberian ginseng, and Indian ayurvedic medicine Ashwagandha on serum digoxin measurement by Digoxin III, a new digoxin immunoassay. Journal of Clinical Laboratory Analysis 22(4): 295-301, 2008

Influence of spironolactone and its metabolite canrenone on serum digoxin assays. Therapeutic Drug Monitoring 12(1): 82-84, 1990

Effect of Asian and Siberian ginseng on serum digoxin measurement by five digoxin immunoassays. Significant variation in digoxin-like immunoreactivity among commercial ginsengs. American Journal of Clinical Pathology 119(2): 298-303, 2003

Rapid detection of oleander poisoning by Digoxin III, a new Digoxin assay: impact on serum Digoxin measurement. American Journal of Clinical Pathology 129(4): 548-553, 2008

Improved procedure for measurement of erythrocyte sodium potassium atpase inhibition in patients on digoxin therapy correlation with serum digoxin levels. Clinical Chemistry 24(6): 1055, 1978